<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="56516"><DrugName>fedratinib</DrugName><DrugNamesKey><Name id="42999357">fedratinib</Name></DrugNamesKey><DrugSynonyms><Name><Value>TG-101193</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TG-101348</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>JAK2 inhibitors (myeloproliferative disorder), TargeGen</Value></Name><Name><Value>JAK-2.V617F inhibitors (MPD), TargeGen</Value></Name><Name><Value>TG-101209</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>dual FLT3/JAK2 inhibitors (myeloproliferative disorders), TargeGen</Value></Name><Name><Value>FLT3/JAK2/Ret inhibitor (myeloproliferative disorders), TargeGen</Value></Name><Name><Value>SAR-302503</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>fedratinib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>936091-26-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29571">TargeGen Inc</CompanyOriginator><CompaniesPrimary><Company id="15331">Celgene Corp</Company></CompaniesPrimary><CompaniesSecondary><Company id="1155296">Impact Biomedicines Inc</Company><Company id="29571">TargeGen Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="56516" type="Drug"><TargetEntity id="441519" type="siDrug">Fedratinib hydrochloride</TargetEntity><TargetEntity id="440220" type="siDrug">TG-101209</TargetEntity></SourceEntity><SourceEntity id="1155296" type="Company"><TargetEntity id="5057951425" type="organizationId">Impact Biomedicines Inc</TargetEntity></SourceEntity><SourceEntity id="15331" type="Company"><TargetEntity id="4295905897" type="organizationId">Celgene Corp</TargetEntity></SourceEntity><SourceEntity id="29571" type="Company"><TargetEntity id="4296694782" type="organizationId">Targegen Inc</TargetEntity></SourceEntity><SourceEntity id="2317" type="ciIndication"><TargetEntity id="1009" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2319" type="ciIndication"><TargetEntity id="D45" type="ICD10"></TargetEntity><TargetEntity id="10036057" type="MEDDRA"></TargetEntity><TargetEntity id="D011087" type="MeSH"></TargetEntity><TargetEntity id="729" type="ORPHANET"></TargetEntity><TargetEntity id="-820147478" type="omicsDisease"></TargetEntity><TargetEntity id="1430" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2436" type="ciIndication"><TargetEntity id="D75.81" type="ICD10"></TargetEntity><TargetEntity id="10028537" type="MEDDRA"></TargetEntity><TargetEntity id="D055728" type="MeSH"></TargetEntity><TargetEntity id="-1044236653" type="omicsDisease"></TargetEntity><TargetEntity id="1634" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="273" type="ciIndication"><TargetEntity id="10028576" type="MEDDRA"></TargetEntity><TargetEntity id="D009196" type="MeSH"></TargetEntity><TargetEntity id="-1904668786" type="omicsDisease"></TargetEntity><TargetEntity id="1247" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3564" type="Action"><TargetEntity id="1505" type="Mechanism">Jak2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3818" type="Action"><TargetEntity id="1922" type="Mechanism">RET Inhibitors</TargetEntity><TargetEntity id="7214" type="Mechanism">Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret (RET; CDHF12; PTC) Activators</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="PTGT-00762" type="ciTarget"><TargetEntity id="212861059123223" type="siTarget">Receptor-type tyrosine-protein kinase FLT3</TargetEntity><TargetEntity id="7001" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01185" type="ciTarget"><TargetEntity id="189436773537173" type="siTarget">Tyrosine-protein kinase JAK2</TargetEntity><TargetEntity id="432" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01670" type="ciTarget"><TargetEntity id="24642065259793" type="siTarget">Proto-oncogene tyrosine-protein kinase receptor Ret</TargetEntity><TargetEntity id="683" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="PR">Pre-registration</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2436">Myelofibrosis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="2317">Thrombocythemia</Indication><Indication id="2319">Polycythemia vera</Indication><Indication id="273">Myeloproliferative disorder</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3818">Ret tyrosine kinase receptor inhibitor</Action><Action id="3564">Jak2 tyrosine kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-27T10:59:59.000Z</LastModificationDate><ChangeDateLast>2019-06-27T00:00:00.000Z</ChangeDateLast><AddedDate>2006-12-12T09:40:21.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1155296" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="15331" linkType="Company"&gt;Celgene&lt;/ulink&gt;, following the acquisition of &lt;ulink linkID="15331" linkType="Company"&gt;Impact Biomedicines&lt;/ulink&gt;,  under license from  &lt;ulink linkID="29571" linkType="Company"&gt;TargeGen&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt;), is developing fedratinib (TG-101348, SAR-302503; structure shown), a Jak2/FLT3/Ret inhibitor that targets the Jak2.V617F and FLT3ITD mutation, for the potential oral capsule treatment of  myelofibrosis [&lt;ulink linkID="1970968" linkType="Reference"&gt;1970968&lt;/ulink&gt;], [&lt;ulink linkID="2033272" linkType="Reference"&gt;2033272&lt;/ulink&gt;], [&lt;ulink linkID="2032173" linkType="Reference"&gt;2032173&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2019,  an NDA was submitted to the FDA for myelofibrosis [&lt;ulink linkID="2113909" linkType="Reference"&gt;2113909&lt;/ulink&gt;], [&lt;ulink linkID="2123171" linkType="Reference"&gt;2123171&lt;/ulink&gt;]; at that time, US approval was expected by the end of 2019 [&lt;ulink linkID="2108879" linkType="Reference"&gt;2108879&lt;/ulink&gt;];  In March 2019, the US FDA accepted the filing with Priority Review, and set a target PDUFA action date of September 03, 2019 [&lt;ulink linkID="2125954" linkType="Reference"&gt;2125954&lt;/ulink&gt;]. In April 2019, the MAA submission was planned by the end of 2019 [&lt;ulink linkID="2145496" linkType="Reference"&gt;2145496&lt;/ulink&gt;]. In October 2018, the drug was expected to be launched by 2020 [&lt;ulink linkID="2086925" linkType="Reference"&gt;2086925&lt;/ulink&gt;]. In January 2019, a phase III trial was to begin in the following month in patients who relapsed from or are intolerant to ruxolitinib [&lt;ulink linkID="2113909" linkType="Reference"&gt;2113909&lt;/ulink&gt;], [&lt;ulink linkID="2115936" linkType="Reference"&gt;2115936&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Impact was previously developing the drug for polycythemia vera (PV)  [&lt;ulink linkID="1970784" linkType="Reference"&gt;1970784&lt;/ulink&gt;]. However, in February 2018, upon  acquisition  by Celgene, the indication was  not listed on its pipeline [&lt;ulink linkID="2033272" linkType="Reference"&gt;2033272&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="29571" linkType="Company"&gt;TargeGen&lt;/ulink&gt; was previously developing fedratinib (TG-101348, SAR-302503; structure shown), a Jak2/FLT3/Ret inhibitor that targets the Jak2.V617F and FLT3ITD mutation, for the potential oral capsule treatment of myeloproliferative disorders (MPDs), including polycythemia vera (PV), thrombocythemia, essential thrombocytosis and myelofibrosis with myeloid metaplasia [&lt;ulink linkID="750464" linkType="Reference"&gt;750464&lt;/ulink&gt;], [&lt;ulink linkID="750465" linkType="Reference"&gt;750465&lt;/ulink&gt;], [&lt;ulink linkID="750337" linkType="Reference"&gt;750337&lt;/ulink&gt;], [&lt;ulink linkID="783535" linkType="Reference"&gt;783535&lt;/ulink&gt;], [&lt;ulink linkID="1233234" linkType="Reference"&gt;1233234&lt;/ulink&gt;]. In  September 2011, TargeGen initiated a phase III trial in patients with patients with primary myelofibrosis, post-PV myelofibrosis or post-essential thrombocythemia myelofibrosis was initiated [&lt;ulink linkID="1245798" linkType="Reference"&gt;1245798&lt;/ulink&gt;]; in May 2013, positive topline data were reported [&lt;ulink linkID="1423249" linkType="Reference"&gt;1423249&lt;/ulink&gt;]. In October 2011, a phase II trial began in patients with  PV and essential thrombocythemia [&lt;ulink linkID="1233234" linkType="Reference"&gt;1233234&lt;/ulink&gt;]. However, in November 2013, Sanofi, as advised by the FDA, halted all clinical trials, cancelled plans to seek regulatory approval and discontinued development of fedratinib due to safety concerns related to reports of cases of Wernicke's encephalopathy in patients in fedratinib trials; at that time, the company was to  investigate the cases of Wernicke's encephalopathy to ensure patient safety; patients receiving fedratinib were to consult with their treating physician to determine the best alternative treatment [&lt;ulink linkID="1500341" linkType="Reference"&gt;1500341&lt;/ulink&gt;], [&lt;ulink linkID="1500432" linkType="Reference"&gt;1500432&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Sanofi was also investigating fedratinib for the potential treatment of solid tumors; a phase I study began in June 2012 [&lt;ulink linkID="1391369" linkType="Reference"&gt;1391369&lt;/ulink&gt;]; however, in November 2013, development of the drug was discontinued [&lt;ulink linkID="1500341" linkType="Reference"&gt;1500341&lt;/ulink&gt;], [&lt;ulink linkID="1500432" linkType="Reference"&gt;1500432&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The compound patent expires in 2026 in the US. In the EU and Japan, the compound patent is also expected to expire in 2026 if pending applications are granted [&lt;ulink linkID="1393823" linkType="Reference"&gt;1393823&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In October 2018, fedratinib was expected to be launched by 2020 [&lt;ulink linkID="2086925" linkType="Reference"&gt;2086925&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In May 2009, the FDA granted the drug Orphan designation for the treatment of secondary and primary myelofibrosis [&lt;ulink linkID="1268282" linkType="Reference"&gt;1268282&lt;/ulink&gt;]. In March 2013, the drug was granted Orphan designation for the treatment of PV [&lt;ulink linkID="1398473" linkType="Reference"&gt;1398473&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, Sanofi expected launch in 2014 [&lt;ulink linkID="1243277" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1243277" linkType="Reference"&gt;1243277&lt;/ulink&gt;]. In November 2013, Sanofi cancelled plans to seek regulatory approval and discontinued development of the drug due to safety concerns related to reports of cases of Wernicke's encephalopathy in patients in fedratinib trials [&lt;ulink linkID="1500341" linkType="Reference"&gt;1500341&lt;/ulink&gt;], [&lt;ulink linkID="1500432" linkType="Reference"&gt;1500432&lt;/ulink&gt;].  In January 2018,  regulatory applications in myelofibrosis were planned for mid-2018, including the submission of an NDA for fedratinib [&lt;ulink linkID="1995620" linkType="Reference"&gt;1995620&lt;/ulink&gt;], [&lt;ulink linkID="1996074" linkType="Reference"&gt;1996074&lt;/ulink&gt;]; in October 2018, the regulatory submission was expected by the end of 2018 [&lt;ulink linkID="2086925" linkType="Reference"&gt;2086925&lt;/ulink&gt;]; in January 2019,  an NDA was submitted to the FDA for myelofibrosis [&lt;ulink linkID="2113909" linkType="Reference"&gt;2113909&lt;/ulink&gt;], [&lt;ulink linkID="2123171" linkType="Reference"&gt;2123171&lt;/ulink&gt;]. At that time, US approval was expected by the end of 2019 [&lt;ulink linkID="2108879" linkType="Reference"&gt;2108879&lt;/ulink&gt;]. In March 2019, the US FDA accepted the filing with Priority Review, and set a target PDUFA date of September 03, 2019 [&lt;ulink linkID="2125954" linkType="Reference"&gt;2125954&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2018, Celgene planned to submit an MAA in 2019 [&lt;ulink linkID="2086925" linkType="Reference"&gt;2086925&lt;/ulink&gt;]. In January 2019,  MAA submission  was expected in 1H19 [&lt;ulink linkID="2108879" linkType="Reference"&gt;2108879&lt;/ulink&gt;]. In April 2019, the MAA submission was planned by the end of 2019 [&lt;ulink linkID="2145496" linkType="Reference"&gt;2145496&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2010, the EMA's COMP recommended granting fedratinib Orphan status for the treatment of primary myelofibrosis; in October 2010, Orphan drug status was granted [&lt;ulink linkID="1268272" linkType="Reference"&gt;1268272&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In October 2012, the Pharmaceutical Affairs and Food Sanitation Council's Second Committee on Drugs was to review Orphan designation for the drug for bone marrow fibrosis at a meeting on October 31, 2012 [&lt;ulink linkID="1338417" linkType="Reference"&gt;1338417&lt;/ulink&gt;]; in November 2012, Orphan designation for myelofibrosis was granted [&lt;ulink linkID="1342632" linkType="Reference"&gt;1342632&lt;/ulink&gt;]. In April 2015, the Orphan Drug designation for myelofibrosis was cancelled in Japan due to the discontinuation of clinical development of fedratinib [&lt;ulink linkID="1655047" linkType="Reference"&gt;1655047&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In November 2013, Sanofi, as advised by the FDA, halted all clinical trials, cancelled plans to seek regulatory approval and discontinued development of fedratinib due to safety concerns related to reports of cases of Wernicke's encephalopathy in patients in fedratinib trials; at that time, the company was to  investigate the cases of Wernicke's encephalopathy to ensure patient safety; patients receiving fedratinib were to consult with their treating physician to determine the best alternative treatment [&lt;ulink linkID="1500341" linkType="Reference"&gt;1500341&lt;/ulink&gt;], [&lt;ulink linkID="1500432" linkType="Reference"&gt;1500432&lt;/ulink&gt;].  However, in October 2017 it was reported that, following a Type A meeting and review of additional data, the FDA had concluded that Impact Biomedicines had provided the necessary documentation to support lifting the clinical hold  [&lt;ulink linkID="1970784" linkType="Reference"&gt;1970784&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Myeloproliferative disorders&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In January 2019, a multicenter, single-arm, open-label, phase IIIb trial (&lt;ulink linkID="361806" linkType="Protocol"&gt;NCT03755518&lt;/ulink&gt;; FREEDOM; FEDR-MF-001; U1111-1223-2862; 2018-002237-38) was to begin in February 2019, to assess the safety and efficacy of fedratinib (400 mg administered once daily) in patients (expected n = 150) with intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis who had been previously treated with &lt;ulink linkID="54662" linkType="Drug"&gt;ruxolitinib&lt;/ulink&gt;. The primary endpoint would be the proportion of subjects with a spleen volume reduction of at least 35% at the end of cycle 6 (each cycle is 28 days). At that time, the trial was expected to complete in June 2022 [&lt;ulink linkID="2115936" linkType="Reference"&gt;2115936&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2013, cases consistent with the neurological disorder Wernicke's encephalopathy were observed in patients in the fedratinib trials; the company subsequently halted all fedratinib trials and discontinued development of the drug [&lt;ulink linkID="1500341" linkType="Reference"&gt;1500341&lt;/ulink&gt;], [&lt;ulink linkID="1500432" linkType="Reference"&gt;1500432&lt;/ulink&gt;]. By October 2017, the FDA concluded that Impact provided the necessary documentation to support lifting the clinical hold; later, the US FDA removed the clinical hold placed on fedratinib following a type A meeting and review of additional data [&lt;ulink linkID="1970784" linkType="Reference"&gt;1970784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, a multinational, randomized, double-blind, placebo-controlled, phase III study (&lt;ulink linkID="80960" linkType="Protocol"&gt;NCT01437787&lt;/ulink&gt;; EFC12153; 2011-001897-25; U1111-1121-7170; JAKARTA) was initiated in patients with primary myelofibrosis, post-PV myelofibrosis or post-essential thrombocythemia myelofibrosis  with splenomegaly (expected n = 225) in the US, Australia, Europe, Brazil, Canada, Israel, Korea, Mexico, Singapore, South Africa and Taiwan, to assess the safety and efficacy of fedratinib. At that time, the study was scheduled to  complete in March 2016 [&lt;ulink linkID="1245798" linkType="Reference"&gt;1245798&lt;/ulink&gt;]. By January 2013, recruitment had been completed  [&lt;ulink linkID="1355153" linkType="Reference"&gt;1355153&lt;/ulink&gt;]. In May 2013, positive topline data were reported, showing that the drug met the primary endpoint of the proportion of patients achieving a 35% or more reduction in spleen volume [&lt;ulink linkID="1423249" linkType="Reference"&gt;1423249&lt;/ulink&gt;]. In December 2013, further data were presented at the 55th ASH Meeting in New Orleans, LA. In the 400 and 500 mg fedratinib groups and placebo group, the respective spleen response rates (&amp;gt;/= 35% reduction in spleen volume from baseline) were 1, 47 and 49% at week 24 and 1, 36 and 40% at week 28. Fedratinib&lt;b&gt; &lt;/b&gt;showed&lt;b&gt; &lt;/b&gt;significant greater improvements in myelofibrosis  symptoms when compared with placebo [&lt;ulink linkID="1503557" linkType="Reference"&gt;1503557&lt;/ulink&gt;]. In December 2013, further data were presented at the 55th ASH Meeting in New Orleans, LA. At the end of cycle 6, the proportion of patients with symptom response and total symptom score (TSS) was significantly higher in the fedratinib groups when compared with placebo. At the end of the treatment, the degree of TSS improvement was greatest in patients with &amp;gt;/= 35% spleen volume reduction from baseline.  When compared with placebo recipients, patients treated with fedratinib experienced greater gains against fatigue [&lt;ulink linkID="1504312" linkType="Reference"&gt;1504312&lt;/ulink&gt;]. In August 2015, data were pulished. Data demonstrated that  ≥35% reduction in spleen volume  at week 24 was observed ≥50% reduction in total symptom score were observed. The primary end point was achieved by 35 of 96 (36% [95% CI, 27%-46%]) and 39 of 97 (40% [95% CI, 30%-50%]) patients in the fedratinib 400-mg and 500-mg groups, vs 1 of 96 (1% [95% CI, 0%-3%]) in the placebo group (p &amp;lt; 0.001). Symptom response rates at week 24 were 33 of 91 (36% [95% CI, 26%-46%]), 31 of 91 (34% [95% CI, 24%-44%]), and 6 of 85 (7% [95% CI, 2%-13%]) in the fedratinib 400-mg, 500-mg, and placebo groups, respectively (p &amp;lt; 0.001). Common adverse events with fedratinib treatment were anemia, gastrointestinal symptoms, and increased levels of liver transaminases, serum creatinine, and pancreatic enzymes. Encephalopathy was reported in 4 women who received fedratinib 500 mg/d. A diagnosis of Wernicke encephalopathy was supported by magnetic resonance imaging in 3 cases and suspected clinically in one case [&lt;ulink linkID="1970940" linkType="Reference"&gt;1970940&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2019, a phase I/II combination trial with &lt;ulink linkID="62259" linkType="Drug"&gt;luspatercept&lt;/ulink&gt; was planned for 2019 [&lt;ulink linkID="2108879" linkType="Reference"&gt;2108879&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In June 2013,  data were presented from a phase II trial (ARD11936; &lt;ulink linkID="80219" linkType="Protocol"&gt;NCT01420770&lt;/ulink&gt;) in 31 patients  at the 49th ASCO meeting in Chicago, IL. Overall, 15 patients at week 12 (primary endpoint) and 24 had &amp;gt; 35% reduction in spleen volume from the baseline. SAR-302503 induced rapid and consistent regulation of 28 cytokines which were mostly involved in immune/inflammatory pathways by &amp;gt;/= 1.5-fold at weeks 4, 8 and 12 [&lt;ulink linkID="1427567" linkType="Reference"&gt;1427567&lt;/ulink&gt;], [&lt;ulink linkID="1748985" linkType="Reference"&gt;1748985&lt;/ulink&gt;];  at week 24, the mean percentage decrease in spleen volume was ranged from 27 to 41%; the mean relative allele burden change was -4.0%. Out of 24 patients, 14 patients inhibited phosphorylated STAT and had a spleen response rate of 58.3 [&lt;ulink linkID="1427565" linkType="Reference"&gt;1427565&lt;/ulink&gt;].  In June 2013, further data were presented at the 18th Annual EHA Congress in Stockholm, Sweden. Patients (n = 31) received daily po doses of SAR-302503 (300, 400 and 500 mg in arms 1, 2 and 3, respectively) in a 4-week cycle. At week 24, &amp;gt;/=50% reduction in the modified myeloproliferative neoplasm symptom assessment form total symptom (MPN-SAF) score was observed in 52% of patients (n = 23). Reduction in spleen volume was significantly associated with the increased adiponectin and decreased TNF-alpha levels [&lt;ulink linkID="1441295" linkType="Reference"&gt;1441295&lt;/ulink&gt;], [&lt;ulink linkID="1440575" linkType="Reference"&gt;1440575&lt;/ulink&gt;]. In December 2013, further data were presented at the 55th ASH Meeting in New Orleans, LA. In the 300, 400 and 500 fedratinib groups, 30, 80 and 45% of patients had achieved spleen response at week 48, respectively.  Of the 25 patients with baseline JAK2V617F mutation, 14 patients achieved spleen response at week 24.  At 300, 400 and 500 dose-levels, the proportion of patients with &amp;gt;/= 50% reduction in total symptom score were 33, 60 and 38%, respectively [&lt;ulink linkID="1504310" linkType="Reference"&gt;1504310&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, a randomized, open-label, phase II trial (&lt;ulink linkID="92607" linkType="Protocol"&gt;NCT01692366&lt;/ulink&gt;; ARD12888, U1111-1130-3710) of the efficacy and safety of fedratinib was initiated in Japanese patients (estimated n = 20) with intermediate-2 or high risk primary myelofibrosis, post-PV myelofibrosis, or post-essential thrombocythemia myelofibrosis with splenomegaly. At that time, the trial was expected to complete in June 2014 [&lt;ulink linkID="1342636" linkType="Reference"&gt;1342636&lt;/ulink&gt;]. In December 2012, results were presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA showing that the drug reduced spleen size and led to an improvement in systemic symptoms [&lt;ulink linkID="1352614" linkType="Reference"&gt;1352614&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2012, a multinational, open-label, single-group, phase II study (&lt;ulink linkID="84500" linkType="Protocol"&gt;NCT01523171&lt;/ulink&gt;; ARD12181; 2011-005226-21; U1111-1124-0967; JAKARTA2) began to assess the efficacy of fedratinib in patients with intermediate- or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis (expected n = 70) who had been previously treated with  &lt;ulink linkID="54662" linkType="Drug"&gt;ruxolitinib&lt;/ulink&gt;. The primary endpoint was response rate. The study was expected to completed in September 2019 [&lt;ulink linkID="1435609" linkType="Reference"&gt;1435609&lt;/ulink&gt;]. In November 2013, the trial was halted due to safety concerns [&lt;ulink linkID="1500341" linkType="Reference"&gt;1500341&lt;/ulink&gt;],  [&lt;ulink linkID="1500432" linkType="Reference"&gt;1500432&lt;/ulink&gt;]. In December 2013, data from 27 patients were presented at the 55th ASH Meeting in New Orleans, LA. Spleen response rates were 40 and 43% in per-protocol population and in patients with baseline platelet count of &amp;lt; 100 x 10(9)/l, respectively. Symptom response was achieved by 19% of patients by week 12 and a majority of patients had a reduction in total symptom score at week 12 [&lt;ulink linkID="1503765" linkType="Reference"&gt;1503765&lt;/ulink&gt;]. In July 2017, data from 97 patients were pulished. Spleen response rate (55%, 95% CI 44–66) was observed in 46 patients, who had failed or were intolerant to ruxolitinib and experienced  a spleen size reduction of ≥35% with fedratinib. Common grade 3–4 adverse events included anaemia (37 [38%] of 97 patients) and thrombocytopenia (21 [22%] of 97), with 18 (19%) patients discontinuing due to adverse events. Seven (7%) patients died during the study, but none of the deaths was drug related. Suspected cases of Wernicke's encephalopathy  in other fedratinib trials (reported in 8 out of 877 patients receiving one or more doses) led to study termination due to clinical hold by the US FDA [&lt;ulink linkID="1970933" linkType="Reference"&gt;1970933&lt;/ulink&gt;], [&lt;ulink linkID="1970784" linkType="Reference"&gt;1970784&lt;/ulink&gt;], [&lt;ulink linkID="1995620" linkType="Reference"&gt;1995620&lt;/ulink&gt;]. In August 2017, the FDA removed the clinical hold placed on fedratinib [&lt;ulink linkID="1995620" linkType="Reference"&gt;1995620&lt;/ulink&gt;]. By February 2019, data had shown that 26% of patients had achieved total symptom score &amp;gt;= 50% at week 24, compared to baseline [&lt;ulink linkID="2131523" linkType="Reference"&gt;2131523&lt;/ulink&gt;]. In June 2019, further data were presented at the 55th ASCO Annual Meeting in Chicago, IL. In the ITT population (n = 97), ruxolitinib failure (n = 79 patients who met at least 1 criterion from the stringent definitions for ruxolitinib relapse/refractory or intolerant) and sensitivity cohorts (66 patients who received 6 fedratinib treatment cycles or discontinued before cycle 6 for reasons other than- study terminated by sponsor), spleen volume response rate (primary endpoint) were 31, 30 and 36%, respectively; and symptom response rate (secondary endpoint) were 27, 27 and 32%, respectively. In ruxolitinib failure cohort and in sensitivity cohorts, the grade 3 to 4 non-hematologic TEAEs reported were diarrhea, fatigue, headache, abdominal pain, dyspnea and  asthenia [&lt;ulink linkID="2155705" linkType="Reference"&gt;2155705&lt;/ulink&gt;], [&lt;ulink linkID="2158848" linkType="Reference"&gt;2158848&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, a multinational, randomized, open-label, phase II study (&lt;ulink linkID="80218" linkType="Protocol"&gt;NCT01420783&lt;/ulink&gt;; ARD12042; 2011-001847-58; U1111-1121-4203) was initiated patients with PV and essential thrombocythemia who are resistant or intolerant to hydroxyurea (expected n = 90), to assess the safety and efficacy of fedratinib. At that time, the study was scheduled to complete in February 2015 [&lt;ulink linkID="1233234" linkType="Reference"&gt;1233234&lt;/ulink&gt;]. In November 2013, the trial was halted due to safety concerns [&lt;ulink linkID="1500341" linkType="Reference"&gt;1500341&lt;/ulink&gt;], [&lt;ulink linkID="1500432" linkType="Reference"&gt;1500432&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, an open-label, non-randomized, single group assignment, safety phase I/II (&lt;ulink linkID="32682" linkType="Protocol"&gt;NCT00724334&lt;/ulink&gt;; MF-TG101348-002) trial was initiated in patients (expected n = 60) with myelofibrosis who had completed the MF-TG101348-001 phase I study.  The primary endpoint was safety and tolerability and the secondary endpoint was to measure clinical activity and pharmacodynamics. The study was expected to be completed in June 2010, and in December 2009, the trial was  ongoing but not recruiting participants [&lt;ulink linkID="1067550" linkType="Reference"&gt;1067550&lt;/ulink&gt;]. By June 2010, the trial had been completed [&lt;ulink linkID="1111868" linkType="Reference"&gt;1111868&lt;/ulink&gt;].  In June 2012,  long-term follow-up clinical data were presented at the 17th EHA Annual Congress in Amsterdam, the Netherlands. From an initial enrollment of 59 patients, 23 remained on treatment by June 2011. At that time, the median dose level received by patients was 440 mg/d. In the study, 59% of patients acheived a &amp;gt; 50% reduction in spleen size from baseline. No unique safety issues were observed [&lt;ulink linkID="1302033" linkType="Reference"&gt;1302033&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In September 2015, data from an exploratory analysis of sequential BMF from two phase I studies (dose-escalation &lt;ulink linkID="32680" linkType="Protocol"&gt;NCT00631462&lt;/ulink&gt; and long-term extension &lt;ulink linkID="32682" linkType="Protocol"&gt;NCT00724334&lt;/ulink&gt;) of  treatment with  fedratinib in patients (n = 21) with myelofibrosis were published. Data demonstrated that improved and stabilised BMF from baseline were recorded in 15 of 18 (83 %) evaluable patients at cycle 6 and in four of nine (44 %) evaluable patients at cycle 30. Two patients achieved resolution of their BMF (grade = 0) by cycle 12 [&lt;ulink linkID="1970926" linkType="Reference"&gt;1970926&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2007, the company expected to file an IND and begin clinical trials in early 2008 [&lt;ulink linkID="755529" linkType="Reference"&gt;755529&lt;/ulink&gt;]. In December 2007, the company announced that its recently filed IND was active and a multicenter clinical trial was expected to begin in January 2008 [&lt;ulink linkID="858441" linkType="Reference"&gt;858441&lt;/ulink&gt;]. In January 2008, TargeGen began a phase I trial (&lt;ulink linkID="32680" linkType="Protocol"&gt;NCT00631462&lt;/ulink&gt;; MF-TG101348-001) of fedratinib for myeloproliferative diseases. The US, multicenter, open-label, dose-escalation study would enroll 40 to 80 patients. The primary endpoint was identification of the maximum tolerated dose (MTD), safety, and the effect on surrogate markers, biomarkers, and presumptive clinical endpoints [&lt;ulink linkID="872618" linkType="Reference"&gt;872618&lt;/ulink&gt;], [&lt;ulink linkID="922082" linkType="Reference"&gt;922082&lt;/ulink&gt;]. In December 2008, clinical data were presented at the 50th ASH meeting in San Francisco, CA, from the ongoing phase I study. Results had not yet been formally acknowledged, but it was established that fedratinib was well tolerated in myelofibrosis patients and a reduction in spleen size had been observed; the trial was ongoing [&lt;ulink linkID="966958" linkType="Reference"&gt;966958&lt;/ulink&gt;]. In February 2009, enrollment of 28 patients in the dose-escalation phase was completed, and in May 2009, enrollment of 31 patients in the dose-confirmation phase was completed [&lt;ulink linkID="1009761" linkType="Reference"&gt;1009761&lt;/ulink&gt;].  In October 2009, the trial was completed [&lt;ulink linkID="1051406" linkType="Reference"&gt;1051406&lt;/ulink&gt;]. In December 2009, data from the trial were presented at the 51st ASH meeting in San Francisco, CA.  Of the 59 patients, 28 were treated in the dose escalation phase and 31 in the dose confirmation phase. A total of 41 patients remained on study following discontinuations due to toxicity. The MTD was 680 mg with Grade 3/4 thombocytopenia and neutropenia observed. Reduction in spleen size was at least 50% in 22 patients and the spleen became non-palpable in 9 subjects [&lt;ulink linkID="1059417" linkType="Reference"&gt;1059417&lt;/ulink&gt;]. In December 2010, clinical data from an extension study in 44 patients were presented at the 52nd ASH meeting in Orlando, FL. A significant reduction in splenomegaly occurred in 65% of patients, and control of leukocytosis and thrombocytosis was also observed [&lt;ulink linkID="1151452" linkType="Reference"&gt;1151452&lt;/ulink&gt;], [&lt;ulink linkID="1156999" linkType="Reference"&gt;1156999&lt;/ulink&gt;]. In December 2011, interim updated safety and efficacy data from the long-term follow-up of patients in the phase I/II trial were presented at the 53rd ASH meeting in San Diego, CA.  Treatment for six cycles was completed by 43 patients, who then continued treatment on the extension study (TED 12015); at that time, 23 patients remained on study. Across all dose-groups after completion of six cycles of treatment, 59.1 and 81.8% of patients achieved a &amp;gt;/=50 and &amp;gt;/=25% reduction in spleen size from baseline, respectively. The spleen became non-palpable in 25% of patients. At the end of cycle 6 across all doses, the median percentage spleen size reduction was 57%. Durable reduction in spleen size and further percentage reduction in spleen size over time was observed in patients in the extension phase. Following treatment, a persistent decrease of median percentage change in allele burden across cycles was observed in patients with &amp;gt;20% JAK2V617F allele burden at baseline (23/51). After cycle 6 across all dose-groups, median WBC counts normalized and remained stable. Platelet-count normalized and remained stable over time at doses &amp;gt;/= 400 mg/day. Of the 34 and 11 patients with leukocytosis and thrombocytosis, respectively, at baseline, WBC and platelet-count normalization was achieved by 50% and 60 to 85% of patients, respectively [&lt;ulink linkID="1246127" linkType="Reference"&gt;1246127&lt;/ulink&gt;]. In April 2013, clinical data were presented at the 104th AACR Meeting in Washington DC. Patients were randomized into 8 dose groups to receive SAR-302503 of doses 10 (group 1) or 30 (group 2) or 80 (group 3) or 150 (group 4) or 300 (group 5) or 500 (group 6) or 680 mg (group 7) or placebo (group 8). Pharmacokinetic data demonstrated that from  groups 1, 2, 3, 4, 5, 6 and 7 Cmax values were 4.95, 32.6, 84.6, 284, 521, 1460 and 1760 ng/ml respectively, tmax results were 2.51, 1.75, 1.75, 2.00, 1.75, 3.00 and 2.50 h, respectively, AUC values were 70.0, 685, 1270, 3260, 6730, 24300 and 29,300 ng.h/ml, respectively, t1/2 values were14.3, 46.1, 38.2, 34.0, 64.3, 78.2 and 62.1 h respectively, apparent total body clearance values were 163, 45.2, 64.6, 53.7, 47.2, 20.9 and 24.2 l/h respectively and Vss values were 1630, 2310, 2710, 1860, 2670, 1220 and 1050 l respectively. Data also demonstrated that at 3 and 24h post dose, a dose-related reduction in pSTAT3 levels were observed in groups 5, 6 and 7 [&lt;ulink linkID="1401631" linkType="Reference"&gt;1401631&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2012, a multicenter, open-label, non-randomized, crossover-group, phase I study (&lt;ulink linkID="86880" linkType="Protocol"&gt;NCT01585623&lt;/ulink&gt;; INT12497; U1111-1125-8930) began in the US to assess the pharmacokinetics and drug interactions of fedratinib in patients with refractory solid tumors (expected n = 12). The primary endpoints were AUC and AUClast when the drug was administered in combination with &lt;ulink linkID="44305" linkType="Drug"&gt;omeprazole&lt;/ulink&gt;, metoprolol and &lt;ulink linkID="44303" linkType="Drug"&gt;midazolam&lt;/ulink&gt;. The study was expected to be completed in November 2012  [&lt;ulink linkID="1391369" linkType="Reference"&gt;1391369&lt;/ulink&gt;]. In November 2013, the trial was halted due to safety concerns [&lt;ulink linkID="1500341" linkType="Reference"&gt;1500341&lt;/ulink&gt;]. In September 2014, data were presented at the 2014 ACCP Annual Meeting in Atlanta, GA. Repeated doses of fedratinib increased the mean AUC of omeprazole, metoprolol, and midazolam by 2.82-, 1.77- and 3.84-fold, respectively. The mean plasma Day 14/Day 1 ratio of 4beta-hydroxycholesterol was 0.59, suggesting a net inhibition of CYP3A4 by fedratinib. Fedratinib Steady-state plasma concentrations of fedratinib were reached by Day 14. Fedratinib was a moderate inhibitor for CYP2C19 and CYP3A4, and a weak inhibitor for CYP2D6 [&lt;ulink linkID="1596786" linkType="Reference"&gt;1596786&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In December 2017, clinical data from a retrospective study were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. Patients (n = 8) from seven countries and five fedratinib studies who received treatment with fedratinib were included in the analysis. During the study, of three patients who were thought to have WE, one was severely malnourished and refused gastrostomy which suggested that malnutrition was a cause of thiamine deficiency. Also, while continuing fedratinib treatment, the other two likely WE patients reported preceding sustained nausea and vomiting with recovery from neurological deficits which suggested that treatment with fedratinib did not inhibit thiamine uptake [&lt;ulink linkID="1993215" linkType="Reference"&gt;1993215&lt;/ulink&gt;], [&lt;ulink linkID="1990666" linkType="Reference"&gt;1990666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, clinical data were presented from a phase I, single-center, open-label, two-period, two-treatment, fixed-sequence, crossover study in 26 healthy subjects at the 116th ASCPT Annual Meeting in New Orleans, LA.  Subjects received two single 500-mg doses of fedratinib  with one dose on day 1 of  period 1 and one dose co-administered with pantoprazole on day 7 of period 2 and pantoprazole (40-mg tablet, qd) on days 1 to 6. Administration of repeated po doses of pantoprazole with a single po dose of fedratinib led to a small and non-relevant increase in fedratinib exposure (9% for Cmax and 15% for AUC).   Fedratinib was generally well tolerated without any serious adverse events [&lt;ulink linkID="1638454" linkType="Reference"&gt;1638454&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014,  data were presented at the 2014 ACCP Annual Meeting in Atlanta, GA, from  on the effect of food on the bioavailability and tolerability of JAK2 inhibitor fedratinib, assessed from two phase I studies in healthy volunteers: FED12258: 100 mg or 500 mg doses under fasted or fed (high-fat breakfast) conditions; and, ALI13451, 500 mg under fasted or fed (low- or high-fat breakfast) conditions). The fed:fasted ratio estimate for area under the plasma concentration versus time curve extrapolated to infinity was 0.96 (100 mg; high-fat/fasted), 1.19 to 1.24 (500 mg; high-fat/fasted) and 1.22 (500 mg; low-fat/fasted). Peak plasma concentration with 500-mg fedratinib was achieved 4 h after a high-fat breakfast and 2 to 2.5 h after a low-fat breakfast or under fasted conditions. The fasted and fed t1/2 for fedratinib was 76 to 88 h and 73 to 78 h, respectively. Adverse events reported the most frequently were mild gastrointestinal toxicities, but these were more frequent with fasted (67%) and low-fat breakfast conditions (59%), compared with high-fat breakfast subjects (17%) [&lt;ulink linkID="1597155" linkType="Reference"&gt;1597155&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014,  data were presented at the 2014 ACCP Annual Meeting in Atlanta, GA, from a phase I, open-label, fixed sequence, non-randomized, 2-period, 2-treatment, 2-cohort drug interaction study of repeated, 14-day oral doses of ketoconazole (200 mg bid) on sequential, ascending, single oral fedratinib in healthy subjects. Coadministration of ketoconazole for 14 days increased fedratinib exposure by 1.85- and 1.93-fold for Cmax after single 50 and 300 mg fedratinib, respectively; increase was by 3.85- and 3.06-fold for AUC, respectively [&lt;ulink linkID="1596795" linkType="Reference"&gt;1596795&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2017, in vitro data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. At physiologically achievable levels, fedratinib treatment did not inhibit thiamine transport in in vitro experiments performed in human serum [&lt;ulink linkID="1993215" linkType="Reference"&gt;1993215&lt;/ulink&gt;],  [&lt;ulink linkID="1990666" linkType="Reference"&gt;1990666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, preclinical data were published. Data demonstrated that JAK-2 inhibitor did not compromise erythrocyte transketolase activity, and thiamine status was not affected. Treatment of cultured astrocytes with fedratinib did not diminish the uptake of thiamine. Fedratinib does not lead to or alter the progress of TD and JAK-2 inhibitor dose not directly result in the development of WE due to inhibition of thiamine transport [&lt;ulink linkID="1970955" linkType="Reference"&gt;1970955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012,  data were presented at the 103rd AACR meeting in Chicago, IL. Treatment with fedratinib (0.1 to 10 microM) for 45 min was sufficient to block both basal and IL-6 induced STAT3 phosphorylation in a dose dependent manner. In all the cell lines tested,  &amp;gt; 50% reduction in the phosphorylated STAT3 levels was observed with fedratinib at concentrations &amp;gt;/= 0.1 microM. At concentrations &amp;lt; 1 microM, this compound inhibited colony formation completely in most of the cell lines. In mice xenotransplanted with DU145 human prostate cancer cells, a significant and dose-dependent inhibition of tumor growth (near to stasis at the highest dose (T/C=19% at 100 mg/kg, bid)) was observed after administration of fedratinib po for 10 days [&lt;ulink linkID="1276547" linkType="Reference"&gt;1276547&lt;/ulink&gt;]. In January 2014, similar preclinical data were presented at the ASCO Genitourinary Cancers Symposium in San Francisco, CA [&lt;ulink linkID="1521706" linkType="Reference"&gt;1521706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, preclinical data were presented at the 50th ASH meeting in San Francisco, CA, where it was concluded that the fedratinib ability to inhibit FIP1L1-PDGFRA+ EOL-1 cell proliferation may be effective in the treatment of chronic eosinophilic leukemia patients with imatinib resistant mutations; further research was ongoing [&lt;ulink linkID="967710" linkType="Reference"&gt;967710&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2008, in vivo data were presented at the 44th annual ASCO meeting in Chicago, IL, showing that fedratinib was efficacious  [&lt;ulink linkID="910552" linkType="Reference"&gt;910552&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, preclinical data were presented at the 49th ASH meeting in Atlanta, GA. In the study, N-ethyl-N-nitrosourea (ENU)-exposed human erythroleukemia (HEL) cells were used to evaluate resistance mutations to fedratinib8. EHNA pretreated HEL cells were exposed to 3 microM of fedratinib. The data showed that 11 mutations were identified and, in the cells bearing the mutations, fedratinib8 did not inhibit STAT5 phosphorylation or cellular proliferation, nor did it induce apoptosis at concentrations up to 3 microM, whereas in wildtype HEL cells it did. The results also showed that other JAK2 inhibitors, derived from a chemically distinct series, were equally potent in wildtype or fedratinib resistant HEL cells [&lt;ulink linkID="859271" linkType="Reference"&gt;859271&lt;/ulink&gt;]. In December 2007, further  preclinical data were presented at the 49th ASH meeting in Atlanta, GA. Fedratinib was evaluated in a number of cell lines with various mutations. HEL, Ba/F3-(MPL)W515L and Ba/F3-V617F cells were inhibited with IC50 values of 300, 620 and 580 nM, respectively.  Colony growth from myeloproliferative disorder patients was greater than in controls, and this was inhibited at nM concentrations. Erythroid colonies were inhibited less potently [&lt;ulink linkID="856284" linkType="Reference"&gt;856284&lt;/ulink&gt;]. The compound was also effective in mouse models of PV [&lt;ulink linkID="859817" linkType="Reference"&gt;859817&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007,  preclinical data were presented at  the 98th AACR meeting in Los Angeles, CA. Fedratinib administered to Baf3/JAK2(V617F) SCID mice   inhibited JAK2 signalling leading to  a dose-dependent   survival advantage. In C57 mice with   an aggressive polycythemia vera-like phenotype induced by bone marrow transplantation with cells expressing JAK2(V617F), oral fedratinib was shown to reverse the polycythemia, leukocytosis, extramedullary hematopoiesis and splenomegaly in a dose-dependent manner. Fedratinib was also shown to inhibit  JAK2-driven tumor growth and cell engraftment in vivo [&lt;ulink linkID="783166" linkType="Reference"&gt;783166&lt;/ulink&gt;]. In further data presented at the same meeting, fedratinib exhibited IC50 values against JAK2 and FLT3 of 3 and 15 nM, respectively, and inhibited proliferation (EC50 = 57 nM) of the human myelomonocytic cell line MV411, which expresses an FLT3 Internal Tandem Duplication (ITD) mutation, suggesting potential treatment value for fedratinib in FLT3ITD-positive AML. The inhibition of downstream signal transduction intermediates suggested that fedratinib functionally inhibits FLT3 and/or JAK2 activity. In human xenograft models in mice (n = 8), fedratinib (120 mg/kg po, bid) caused the complete regression of MV411 tumors after 22 days [&lt;ulink linkID="784855" linkType="Reference"&gt;784855&lt;/ulink&gt;], [&lt;ulink linkID="783535" linkType="Reference"&gt;783535&lt;/ulink&gt;]. In June 2007, similar preclinical data were presented at the 43rd ASCO meeting in Chicago, IL [&lt;ulink linkID="796128" linkType="Reference"&gt;796128&lt;/ulink&gt;]. In December 2007, similar preclinical data  were presented at the 49th ASH meeting in Atlanta, GA [&lt;ulink linkID="857806" linkType="Reference"&gt;857806&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2007,  preclinical data on the Jak2 inhibitor series were presented at the 233rd ACS National Meeting in Chicago, IL. Disubstituted sulfonamide inhibitors displayed increased selectivity for Jak2 over Jak3, and monosubstituted sulfonamide derivatives with branched alkyl-moieties further enhanced this aspect. A tert-butyl sulfonamide series was optimized for its selectivity and potency. This series showed good potency for Jak2, with IC50 values ranging from 5 to 40 nM, and good selectivity for Jak2 over Jak3, with a 30- to 120-fold increase in selectivity. Hetero-aryl derivatives in the series were selected for their tolerability and selectivity, one with a Jak2 IC50 value of 12 nM compared with a Jak3 IC50 value of 1490 nM, representing a 124-fold increase. In vitro, an undisclosed lead compound potently inhibited Jak2.V617F-mutant-driven cell proliferation in human erthyroid leukemia cells (HEL), and inhibited Jak2.V617F-mediated protein phosphorylation and induced apoptosis in Jak2.V617F cell lines. In vivo, it increased survival times and reduced cell burden in Jak2.V617F circulating tumor models. Survival times were attributed to inhibition of Jak2 downstream signaling [&lt;ulink linkID="772784" linkType="Reference"&gt;772784&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in March 2007, preclinical data were presented at the Molecular Targets for Cancer meeting in Whistler, British Columbia, Canada. Fedratinib inhibited Jak2 with an in vitro IC50 value of 3 nM, and was 332-fold selective for Jak2 compared to Jak3. In cellular assays, the compound inhibited cell proliferation with an IC50 value of approximately 300 nM, which correlated with inhibition of Stat5 phosphorylation. In human hematopoietic stem cells overexpressing either wild type or Jak2.V617F mutant, both in vitro and in vivo experiments showed that fedratinib preferentially affected cells with the mutant kinase. In a murine model of Jak2.V617F-induced myeloproliferative disease, fedratinib was shown to substantially reduce hematocrit, leucocytosis and splenomegaly [&lt;ulink linkID="779988" linkType="Reference"&gt;779988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, preclinical data on Jak2 inhibitors were presented at the 48th ASH meeting in Orlando, FL. In preclinical studies fedratinib reduced Jak2-induced STAT5-phosphorylation and inhibited apoptosis in a dose-dependent manner. Compounds were identified which potently inhibited Jak2 enzyme, with enzymatic IC50s as low as 1 nM, and in Jak2.V617F transformed cell lines, compounds were identified with proliferation EC50 values as low as 60 nM. Several of the compounds were found to increase survival and reduce Jak2.V617F cell burden following oral dosing of the drug in a rodent model at 10-, 30- and 100-mg/kg doses. Promising pharmacokinetic data were obtained from multiple species where oral availability of &amp;gt; 20% and a half-life consistent with 1- to 2-day dosing were observed. In cell proliferation assays, TG-101209  inhibited Jak2-expressing Ba/F3 cells and Jak2.V617F-homozygous human erythroleukemia (HEL) cells with IC50 values of 280 and 300 nM, respectively, but not BCR-ABL-carrying K562 cells (IC50 &amp;gt; 2 M). At 24 h, 600 nM TG-101209 induced apoptosis of HEL cells, but not K562 cells (40 and 5%, respectively) [&lt;ulink linkID="750464" linkType="Reference"&gt;750464&lt;/ulink&gt;], [&lt;ulink linkID="750337" linkType="Reference"&gt;750337&lt;/ulink&gt;], [&lt;ulink linkID="750585" linkType="Reference"&gt;750585&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In October 2012, the EMA's Pediatric Committee adopted a positive opinion for product-specific waiver [&lt;ulink linkID="1331001" linkType="Reference"&gt;1331001&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-24T00:00:00.000Z</StatusDate><Source id="2113909" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-10-25T00:00:00.000Z</StatusDate><Source id="2086925" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500341" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29571">TargeGen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-11-18T00:00:00.000Z</StatusDate><Source id="1500432" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1155296">Impact Biomedicines Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-12T00:00:00.000Z</StatusDate><Source id="2030838" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-06T00:00:00.000Z</StatusDate><Source id="1137334" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-07-31T00:00:00.000Z</StatusDate><Source id="1067550" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1342636" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1342636" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-10T00:00:00.000Z</StatusDate><Source id="1342636" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-04-02T00:00:00.000Z</StatusDate><Source id="1276547" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="273">Myeloproliferative disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-01-31T00:00:00.000Z</StatusDate><Source id="872618" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-30T00:00:00.000Z</StatusDate><Source id="1391369" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-13T00:00:00.000Z</StatusDate><Source id="1342636" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-13T00:00:00.000Z</StatusDate><Source id="1342636" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-21T00:00:00.000Z</StatusDate><Source id="1233234" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2317">Thrombocythemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-13T00:00:00.000Z</StatusDate><Source id="1342636" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-09T00:00:00.000Z</StatusDate><Source id="1245798" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1155296">Impact Biomedicines Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2319">Polycythemia vera</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-13T00:00:00.000Z</StatusDate><Source id="1970784" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1155296">Impact Biomedicines Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-10-13T00:00:00.000Z</StatusDate><Source id="1970784" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-12T00:00:00.000Z</StatusDate><Source id="2030838" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29571">TargeGen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="273">Myeloproliferative disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-12-11T00:00:00.000Z</StatusDate><Source id="750464" type="CONFERENCE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009547">Sanofi SA</OwnerCompany><Country id="AU">Australia</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>For the treatment of primary myelofibrosis, of post-polycythaemia vera myelofibrosis and of post-essential thrombocythaemia myelofibrosis.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009547">Sanofi SA</OwnerCompany><Country id="JP">Japan</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-25T00:00:00.000Z</MileStoneDate><Source id="1655047" type="SERIAL"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="US">US</Country><Indication id="2319">Polycythemia vera</Indication><AwardedIndication>Treatment of polycythemia vera</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-03-21T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009547">Sanofi SA</OwnerCompany><Country id="JP">Japan</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-11-14T00:00:00.000Z</MileStoneDate><Source id="1342632" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of post-essential thrombocythaemia myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of post-polycythaemia vera myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-10-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of primary myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-02-28T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of post-essential thrombocythaemia myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-26T00:00:00.000Z</MileStoneDate><Source id="1268272" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of post-polycythaemia vera myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-26T00:00:00.000Z</MileStoneDate><Source id="1268272" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of primary myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-10-01T00:00:00.000Z</MileStoneDate><Source id="1268272" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of post-polycythaemia vera myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-09T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of post-essential thrombocythaemia myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-09T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of primary myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-07-16T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29571">TargeGen Inc</OwnerCompany><Country id="US">US</Country><Indication id="2436">Myelofibrosis</Indication><AwardedIndication>Treatment of secondary and primary myelofibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-05-18T00:00:00.000Z</MileStoneDate><Source id="1268282" type="OTHER"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00762"><Name>Flt3 tyrosine kinase</Name><SwissprotNumbers><Swissprot>P36888</Swissprot><Swissprot>Q00342</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01185"><Name>Jak2 tyrosine kinase</Name><SwissprotNumbers><Swissprot>O60674</Swissprot><Swissprot>Q62120</Swissprot><Swissprot>Q62689</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01670"><Name>Ret tyrosine kinase receptor</Name><SwissprotNumbers><Swissprot>P07949</Swissprot><Swissprot>P35546</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1157701">Oberland Capital Management LLC</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15331">Celgene Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>4</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="20">Company - M&amp;A (in whole or part)</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4</Smiles><Smiles>Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)N4CCN(CC4)C</Smiles></StructureSmiles><Deals><Deal id="243457" title="Impact to develop TargeGen's fedratinib for MF, PV and thrombocythemia "></Deal><Deal id="244428" title="Oberland to award Impact funding to advance the development of fedratinib against ruxolitinib resistant or intolerant MF and PV"></Deal><Deal id="244987" title="Celgene acquires Impact Biomedicines"></Deal><Deal id="252577" title="Bristol-Myers Squibb to acquire Celgene to create a biopharma company focused on cancer, inflammatory, immunologic disease and cardiovascular diseases"></Deal></Deals><PatentFamilies><PatentFamily id="1242033" number="WO-2012061537" title="Methods for treating hair loss disorders"></PatentFamily><PatentFamily id="1607741" number="WO-2007053452" title="Bi-aryl meta-pyrimidine inhibitors of kinases"></PatentFamily><PatentFamily id="2220960" number="WO-2009073575" title="Methods for treating induced cellular proliferative disorders"></PatentFamily><PatentFamily id="2458361" number="WO-2013013195" title="Compositions and methods for treating polycythemia vera and essential thrombocythemia"></PatentFamily><PatentFamily id="2517717" number="WO-2013059548" title="Compositions and methods for treating cancer using JAK-2 inhibitor"></PatentFamily><PatentFamily id="2728507" number="WO-2014068072" title="Identification, assessment and therapy of essential thrombocythemia with resistance to JAK2 inhibitors"></PatentFamily><PatentFamily id="2811059" number="WO-2014161046" title="Methods of treating diseases characterized by excessive Wnt signalling"></PatentFamily><PatentFamily id="2834737" number="WO-2014189996" title="Anti-tumor therapy"></PatentFamily><PatentFamily id="2857685" number="WO-2015002766" title="Anti-tumor therapy"></PatentFamily><PatentFamily id="3070141" number="WO-2012060847" title="Compositions and methods for treating myelofibrosis"></PatentFamily><PatentFamily id="48208" number="WO-2010017122" title="Methods of treating thalassemia"></PatentFamily><PatentFamily id="514675" number="WO-2008057233" title="Models of erythropoiesis"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>7</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Do-Coop Technologies Ltd" id="1022362"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aclaris Therapeutics Inc" id="1075759"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vixen Pharmaceuticals Inc" id="1121408"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="INSERM" id="17229"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of California" id="20547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Columbia University" id="20559"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Melbourne" id="20620"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Pierre et Marie Curie" id="20660"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut Gustave Roussy" id="21081"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Walter and Eliza Hall Institute of Medical Research" id="21082"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oregon Health Sciences University" id="22708"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Assistance Publique Hopitaux de Paris" id="23948"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Chicago" id="26013"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>